SPOTLIGHT: Novartis touts mid-stage results for MS drug
Novartis said that a mid-stage trial of an oral multiple sclerosis drug demonstrated sustained benefits and good tolerability in patients. The results will clear the way for discussions with the FDA for a Phase III trial to begin next year. Story
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
